A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran

References

• Dorgalaleh A, Dadashizadeh G, Bamedi T. Hemophilia in Iran. Hematol J. 2016;21(5):300–310.
   Google Scholar
• Coppola A, Di Capua M, De Simone C. Primary prophylaxis in children with haemophilia. Blood Transfus. 2008;6(2):4–11.
   Google Scholar
• Noone D, O’Mahony B, Prihodova L. A survey of the outcome of prophylaxis, on-demand or combined treatment in 20–35 year old men with severe haemophilia in four European countries. Haemophilia. 2011;17(5):e842.
   PubMed Web of Science ®Google Scholar
• Colombo GL, Di Matteo S, Mancuso ME, et al. Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A. Clinicoecon Outcomes Res. 2011;3:55–61.
   PubMedGoogle Scholar
• Risebrough N, Oh P, Blanchette V, et al. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia. 2008;14(4):743–752.
   PubMed Web of Science ®Google Scholar
• Henry N, Jovanović J, Schlueter M, et al. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden. J Med Econ. 2018;21(4):318–325.
   PubMed Web of Science ®Google Scholar
• Fischer K, Van der Bom G, Molho P, et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia. 2002;8(6):745–752.
   PubMed Web of Science ®Google Scholar
• Witmer C, Presley R, Kulkarni R, et al. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol. 2011;152(2):211–216.
   PubMed Web of Science ®Google Scholar
• Karimi M, Eshghi P, Safarpour M, et al. Modified Primary prophylaxis in previously Untreated patients With severe hemophilia A in Iran. J Pediatr Hematol Oncol. 2018;40(3):188–191.
   PubMed Web of Science ®Google Scholar
• Fernandes S, Carvalho M, Lopes M, et al. Impact of an individualized prophylaxis approach on young adults with severe hemophilia. Semin Thromb Hemost. 2014;40(07):785–789.
   PubMedGoogle Scholar
• Daliri AA, Haghparast H, Mamikhani J. Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran. Int J Technol Assess Health Care. 2009;25(4):584–587.
   PubMed Web of Science ®Google Scholar
• Miners H, Sabin A, Tolley H, et al. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics. 2002;20(11):759–774.
   PubMed Web of Science ®Google Scholar
• Dalton R. Hemophilia in the managed care setting. Am J Manag Care. 2015;21(6 Suppl):S123–SS30.
   PubMed Web of Science ®Google Scholar
• Globe R, Cunningham E, Andersen R, et al. The hemophilia utilization group study (HUGS): determinants of costs of care in persons with haemophilia A. Haemophilia. 2003 May;9(3):325–331.
   PubMed Web of Science ®Google Scholar
• Blanchette S, O'Mahony B, McJames L, et al. Assessment of outcomes- what is the added value of QoL tools? Haemophilia. 2014 May;20(4):114–120.
   PubMedGoogle Scholar
• Berger K, Schopohl D, Eheberg D, et al. Prophylactic factor substitution in severe haemophilia A. Hämostaseologie. 2014;34(4):291–300.
   PubMed Web of Science ®Google Scholar
• Fischer K, Lewandowski D, Janssen M. Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A. Haemophilia. 2016;22(5):e375–e382.
   PubMed Web of Science ®Google Scholar
• Klamroth R, Pollmann H, Hermans C, et al. The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-authorization Safety Surveillance (PASS) study. Haemophilia. 2011;17(3):412–421.
   PubMed Web of Science ®Google Scholar
• Szucs T, Öffner A, Schramm W. Socioeconomic impact of haemophilia care: results of a pilot study. Haemophilia. 1996;2(4):211–217.
   PubMed Web of Science ®Google Scholar
• Miners H. Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much? Haemophilia. 2013 Mar;19(2):174–180.
   PubMed Web of Science ®Google Scholar
• Purchasing Power Parity. WHO; 2017 [updated 2017; cited 2017 Oct 1]; Available from: http://www.who.int/choice/costs/ppp/en/.
   Google Scholar
• Saulyte Trakymiene S, Ingerslev J, Rageliene L. Utility of the Haemophilia joint health score in study of episodically treated boys with severe haemophilia A and B in Lithuania. Haemophilia. 2010;16(3):479–486.
   PubMed Web of Science ®Google Scholar
• Beheshtipoor N, Bagheri S, Hashemi F, et al. The effect of yoga on the quality of life in the children and adolescents with haemophilia. Int J Community Based Nurs Midwifery. 2015 Apr;3(2):150–155.
   PubMedGoogle Scholar
• Barr RD, Saleh M, Furlong W, et al. Health status and health-related quality of life associated with hemophilia. Am J Hematol. 2002 Nov;71(3):152–160.
   PubMed Web of Science ®Google Scholar
• Ravangard R, Rezaee M , Keshavarz K, Borhanihaghighi A, et al. Cost-effectiveness and cost-utility of CinnoVex versus ReciGen in patients with relapsing-remitting multiple sclerosis in Iran. Shiraz E-Med J. 2018;19(11):e67363–e67371.
   Google Scholar
• Gharibnaseri Z, Davari M, Cheraghali A, et al. Cost-utility of prophylaxis VS. On-demand treatment In severe Haemophilia A patients. Value Health. 2016;19(7):A591.
   Google Scholar
• Salinas-Escudero G, Marıa G-SR, Kely R, et al. Cost-effectiveness analysis of prophylaxis vs.‘on demand’approach in the management in children with hemophilia A in Mexico. Bol Med Hosp Infant Mex. 2013;70(4):290, Ā7.
   Google Scholar
• Lippert B, Berger K, Berntorp E, et al. Cost effectiveness of haemophilia treatment: a cross-national assessment. Blood Coagul Fibrinolysis. 2005;16(7):477–485.
   PubMed Web of Science ®Google Scholar
• Karimi M, Eshghi P, Toogeh G, et al. Comprehensive management for hemophilia in Iran. 1st ed. Tehran: Ministry of Health and Medical Education; 2008.
   Google Scholar
• Giordano P, Lassandro G, Valente M, et al. Current management of the hemophilic child: a demanding interlocutor. quality of life and Adequate cost-Efficacy Analysis. J Pediatr Hematol Oncol. 2014;31(8):687–702.
   Google Scholar
• Farrugia A, Cassar J, Kimber M, et al. Treatment for life for severe haemophilia A–A cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia. 2013;19(4):e228–e238.
   PubMed Web of Science ®Google Scholar
• Chaugule SS, Hay JW, Young G. Understanding patient preferences and willingness to pay for hemophilia therapies. Patient Prefer Adherence. 2015;9:1623–1630.
   PubMed Web of Science ®Google Scholar
• Fischer K, Pouw M, Lewandowski E, et al. A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A. Haematologica. 2011;96(5):738–743.
   PubMed Web of Science ®Google Scholar
• Castro Jaramillo HE, Moreno Viscaya M, Mejia AE. Cost-utility analysis of primary prophylaxis, compared with on-demand treatment, for patients with severe hemophilia type a in Colombia. Int J Technol Assess Health Care. 2016;32(5):337–347.
   PubMed Web of Science ®Google Scholar
• Smith PS, Teutsch SM, Shaffer PA, et al. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr. 1996;129(3):424–431.
   PubMed Web of Science ®Google Scholar
• Manco-Johnson M, Abshire T, Shapiro A, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;6(357):535–544.
   Google Scholar
• Valentino L, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia a management. J Thromb Haemost. 2012;10(3):359–367.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Schutgens RE, Santagostino E, et al. How I treat age-related morbidities in elderly persons with hemophilia. Blood. 2009 Dec 17;114(26):5256–5263.
   PubMed Web of Science ®Google Scholar
• Population and Migration Information and Statistics Office. National Organization for Civil Registration; 2017 [updated 2017; cited]; Available from: https://www.sabteahval.ir/avej/tab-1499.aspx.
   Google Scholar
• van Genderen R, van Meeteren L, van der Bom G, et al. Haemophilia activities list – pediatric (PedHAL) World Federation of Hemophilia; [cited 2016 May 22]; Available from: http://www.wfh.org/en/page.aspx?pid=875.
   Google Scholar